Cold Sensing by Nav1.8-Positive and Nav1.8-Negative Sensory Neurons
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Analysis of the Shaker Gene Complex of Drosophila Melanogaster
Copyright 0 1990 by the Genetics Society of America Genetic Analysisof the Shaker Gene Complexof Drosophila melanogaster A. Ferriis,* S. LLamazares,* J. L. de la Pornpa,* M. A. Tanouye? and0. Pongs* *Institute Cajal, CSIC, 28006 Madrid, Spain, +California Instituteof Technology, Pasadena, California 91 125, and 'Ruhr Universitat,Bochum, Federal Republic of Germany Manuscript received May 10, 1989 Accepted for publication March 3, 1990 ABSTRACT The Shaker complex (ShC) spans over 350 kb in the 16F region of the X chromosome. It can be dissected by means of aneuploids into three main sections: the maternal effect (ME), the viable (V) and the haplolethal (HL) regions. The mutational analysis of ShC shows a high density of antimorphic mutations among 12 lethal complementation groupsin addition to 14 viable alleles. The complex is the structural locus of a family of potassium channels as well as a number of functions relevant to the biology of the nervous system. The constituents of ShC seem to be linked by functional relationships in view of the similarity of the phenotypes, antimorphic nature of their mutations and the behavior in transheterozygotes. We discuss the relationship between the genetic organization of ShC and the functional coupling of potassium currents with the other functions encodedin the complex. HAKER was the first behavioral mutant detected do not appear tohave the capability of generating, by S in Drosophila melanogaster (CATSCH1944). It was themselves, gated ionic channels. named after another mutantwith a similar phenotype K+ currents are known to be themost diverse class isolated earlier in Drosophila funebris (LUERS 1936). of ionic currents in terms of kinetics, pharmacology The original phenotype was described as the trem- and sensitivity (HILLE 1984; RUDY 1988).Also, these bling of appendagesin the anesthetized fly. -
Biological Toxins Fact Sheet
Work with FACT SHEET Biological Toxins The University of Utah Institutional Biosafety Committee (IBC) reviews registrations for work with, possession of, use of, and transfer of acute biological toxins (mammalian LD50 <100 µg/kg body weight) or toxins that fall under the Federal Select Agent Guidelines, as well as the organisms, both natural and recombinant, which produce these toxins Toxins Requiring IBC Registration Laboratory Practices Guidelines for working with biological toxins can be found The following toxins require registration with the IBC. The list in Appendix I of the Biosafety in Microbiological and is not comprehensive. Any toxin with an LD50 greater than 100 µg/kg body weight, or on the select agent list requires Biomedical Laboratories registration. Principal investigators should confirm whether or (http://www.cdc.gov/biosafety/publications/bmbl5/i not the toxins they propose to work with require IBC ndex.htm). These are summarized below. registration by contacting the OEHS Biosafety Officer at [email protected] or 801-581-6590. Routine operations with dilute toxin solutions are Abrin conducted using Biosafety Level 2 (BSL2) practices and Aflatoxin these must be detailed in the IBC protocol and will be Bacillus anthracis edema factor verified during the inspection by OEHS staff prior to IBC Bacillus anthracis lethal toxin Botulinum neurotoxins approval. BSL2 Inspection checklists can be found here Brevetoxin (http://oehs.utah.edu/research-safety/biosafety/ Cholera toxin biosafety-laboratory-audits). All personnel working with Clostridium difficile toxin biological toxins or accessing a toxin laboratory must be Clostridium perfringens toxins Conotoxins trained in the theory and practice of the toxins to be used, Dendrotoxin (DTX) with special emphasis on the nature of the hazards Diacetoxyscirpenol (DAS) associated with laboratory operations and should be Diphtheria toxin familiar with the signs and symptoms of toxin exposure. -
Chemical Synthesis, Proper Folding, Nav Channel Selectivity Profile And
toxins Article Chemical Synthesis, Proper Folding, Nav Channel Selectivity Profile and Analgesic Properties of the Spider Peptide Phlotoxin 1 1, 2,3, 4,5, 1 Sébastien Nicolas y, Claude Zoukimian y, Frank Bosmans y,Jérôme Montnach , Sylvie Diochot 6, Eva Cuypers 5, Stephan De Waard 1,Rémy Béroud 2, Dietrich Mebs 7 , David Craik 8, Didier Boturyn 3 , Michel Lazdunski 6, Jan Tytgat 5 and Michel De Waard 1,2,* 1 Institut du Thorax, Inserm UMR 1087/CNRS UMR 6291, LabEx “Ion Channels, Science & Therapeutics”, F-44007 Nantes, France; [email protected] (S.N.); [email protected] (J.M.); [email protected] (S.D.W.) 2 Smartox Biotechnology, 6 rue des Platanes, F-38120 Saint-Egrève, France; [email protected] (C.Z.); [email protected] (R.B.) 3 Department of Molecular Chemistry, Univ. Grenoble Alpes, CNRS, 570 rue de la chimie, CS 40700, 38000 Grenoble, France; [email protected] 4 Faculty of Medicine and Health Sciences, Department of Basic and Applied Medical Sciences, 9000 Gent, Belgium; [email protected] 5 Toxicology and Pharmacology, University of Leuven, Campus Gasthuisberg, P.O. Box 922, Herestraat 49, 3000 Leuven, Belgium; [email protected] (E.C.); [email protected] (J.T.) 6 Université Côte d’Azur, CNRS UMR7275, Institut de Pharmacologie Moléculaire et Cellulaire, 660 route des lucioles, 6560 Valbonne, France; [email protected] (S.D.); [email protected] (M.L.) 7 Institute of Legal Medicine, University of Frankfurt, Kennedyallee 104, 60488 Frankfurt, Germany; [email protected] 8 Institute for Molecular Bioscience, University of Queensland, Brisbane 4072, Australia; [email protected] * Correspondence: [email protected]; Tel.: +33-228-080-076 Contributed equally to this work. -
Expression Profiling of Ion Channel Genes Predicts Clinical Outcome in Breast Cancer
UCSF UC San Francisco Previously Published Works Title Expression profiling of ion channel genes predicts clinical outcome in breast cancer Permalink https://escholarship.org/uc/item/1zq9j4nw Journal Molecular Cancer, 12(1) ISSN 1476-4598 Authors Ko, Jae-Hong Ko, Eun A Gu, Wanjun et al. Publication Date 2013-09-22 DOI http://dx.doi.org/10.1186/1476-4598-12-106 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Ko et al. Molecular Cancer 2013, 12:106 http://www.molecular-cancer.com/content/12/1/106 RESEARCH Open Access Expression profiling of ion channel genes predicts clinical outcome in breast cancer Jae-Hong Ko1, Eun A Ko2, Wanjun Gu3, Inja Lim1, Hyoweon Bang1* and Tong Zhou4,5* Abstract Background: Ion channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial. Methods: We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman’s rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test. -
Targeted Neuronal Cell Ablation in the Drosophila Embryo: Pathfinding by Follower Growth Cones in the Absence of Pioneers
Neuron, Vol. 14, 707-715, April, 1995, Copyright© 1995 by Cell Press Targeted Neuronal Cell Ablation in the Drosophila Embryo: Pathfinding by Follower Growth Cones in the Absence of Pioneers David M. Lin,* Vanessa J. Auld,*t reach their targets in the CNS (Wigglesworth, 1953). The and Corey S. Goodman ability of the initial axons to guide later growth cones has Howard Hughes Medical Institute led to the suggestion that pioneering growth cones might Division of Neurobiology be endowed with special pathfinding abilities. Do subse- Department of Molecular and Cell Biology quent growth cones possess the same pathfinding abili- Life Science Addition, Room 519 ties, or are they different from the pioneers? University of California, Berkeley Ablation experiments in a variety of organisms thus far Berkeley, California 94720 have provided a range of conflicting answers to this ques- tion. In the grasshopper embryo CNS, the G growth cone turns anteriorly along the P axons in the NP fascicle, a Summary pathway formed by the three descending P and the two ascending A axons. Although the A and P axons normally We developed a rapid method that uses diphtheria fasciculate and follow one another, either can pioneer the toxin, the flp recognition target sequences, and the complete pathway on its own. Furthermore, any one of GAL4-UAS activation system, to ablate specific neu- the P axons will suffice, since when any two of them are rons in the Drosophila embryo and to examine the con- ablated the remaining P pioneers the pathway. When the sequences in large numbers of embryos at many time three P axons are ablated, the G growth cone stalls, and points. -
Mapping Protein Interactions of Sodium Channel Nav1.7 Using 2 Epitope-Tagged Gene Targeted Mice
bioRxiv preprint doi: https://doi.org/10.1101/118497; this version posted March 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Mapping protein interactions of sodium channel NaV1.7 using 2 epitope-tagged gene targeted mice 3 Alexandros H. Kanellopoulos1†, Jennifer Koenig1, Honglei Huang2, Martina Pyrski3, 4 Queensta Millet1, Stephane Lolignier1, Toru Morohashi1, Samuel J. Gossage1, Maude 5 Jay1, John Linley1, Georgios Baskozos4, Benedikt Kessler2, James J. Cox1, Frank 6 Zufall3, John N. Wood1* and Jing Zhao1†** 7 1Molecular Nociception Group, WIBR, University College London, Gower Street, 8 London WC1E 6BT, UK. 9 2Mass Spectrometry Laboratory, Target Discovery Institute, University of Oxford, The 10 Old Road Campus, Oxford, OX3 7FZ, UK. 11 3Center for Integrative Physiology and Molecular Medicine, Saarland University, 12 Kirrbergerstrasse, Bldg. 48, 66421 Homburg, Germany. 13 4Division of Bioscience, University College London, Gower Street, London WC1E 6BT, UK.14 15 †These authors contributed equally to directing this work. 16 *Correspondence author. Tel: +44 207 6796 954; E-mail: [email protected] 17 **Corresponding author: Tel: +44 207 6790 959; E-mail: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/118497; this version posted March 20, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 The voltage-gated sodium channel NaV1.7 plays a critical role in pain pathways. 20 Besides action potential propagation, NaV1.7 regulates neurotransmitter release, 21 integrates depolarizing inputs over long periods and regulates transcription. -
Allosteric Features of KCNQ1 Gating Revealed by Alanine Scanning Mutagenesis
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biophysical Journal Volume 100 February 2011 885–894 885 Allosteric Features of KCNQ1 Gating Revealed by Alanine Scanning Mutagenesis Li-Juan Ma, Iris Ohmert, and Vitya Vardanyan* Institut fu¨r Neurale Signalverarbeitung, Zentrum fu¨r Molekulare Neurobiologie, Universita¨t Hamburg, Hamburg, Germany ABSTRACT Controlled opening and closing of an ion-selective pathway in response to changes of membrane potential is a fundamental feature of voltage-gated ion channels. In recent decades, various details of this process have been revealed with unprecedented precision based on studies of prototypic potassium channels. Though current scientific efforts are focused more on a thorough description of voltage-sensor movement, much less is known about the similarities and differences of the gating mechanisms among potassium channels. Here, we describe the peculiarities of the KCNQ1 gating process in parallel comparison to Shaker. We applied alanine scanning mutagenesis to the S4-S5 linker and pore region and followed the regular- ities of gating perturbations in KCNQ1. We found a fractional constitutive conductance for wild-type KCNQ1. This component increased significantly in mutants with considerably leftward-shifted steady-state activation curves. In contrast to Shaker,no correlation between V1/2 and Z parameters was observed for the voltage-dependent fraction of KCNQ1. Our experimental find- ings are explained by a simple allosteric gating scheme with voltage-driven and voltage-independent transitions. Allosteric features are discussed in the context of extreme gating adaptability of KCNQ1 upon interaction with KCNE b-subunits. -
Engineering Biosynthetic Excitable Tissues from Unexcitable Cells for Electrophysiological and Cell Therapy Studies
ARTICLE Received 11 Nov 2010 | Accepted 5 Apr 2011 | Published 10 May 2011 DOI: 10.1038/ncomms1302 Engineering biosynthetic excitable tissues from unexcitable cells for electrophysiological and cell therapy studies Robert D. Kirkton1 & Nenad Bursac1 Patch-clamp recordings in single-cell expression systems have been traditionally used to study the function of ion channels. However, this experimental setting does not enable assessment of tissue-level function such as action potential (AP) conduction. Here we introduce a biosynthetic system that permits studies of both channel activity in single cells and electrical conduction in multicellular networks. We convert unexcitable somatic cells into an autonomous source of electrically excitable and conducting cells by stably expressing only three membrane channels. The specific roles that these expressed channels have on AP shape and conduction are revealed by different pharmacological and pacing protocols. Furthermore, we demonstrate that biosynthetic excitable cells and tissues can repair large conduction defects within primary 2- and 3-dimensional cardiac cell cultures. This approach enables novel studies of ion channel function in a reproducible tissue-level setting and may stimulate the development of new cell-based therapies for excitable tissue repair. 1 Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708, USA. Correspondence and requests for materials should be addressed to N.B. (email: [email protected]). NatURE COMMUNicatiONS | 2:300 | DOI: 10.1038/ncomms1302 | www.nature.com/naturecommunications © 2011 Macmillan Publishers Limited. All rights reserved. ARTICLE NatUre cOMMUNicatiONS | DOI: 10.1038/ncomms1302 ll cells express ion channels in their membranes, but cells a b with a significantly polarized membrane that can undergo e 0 a transient all-or-none membrane depolarization (action A 1 potential, AP) are classified as ‘excitable cells’ . -
Redalyc.Neurobiological Alterations in Alcohol Addiction: a Review
Adicciones ISSN: 0214-4840 [email protected] Sociedad Científica Española de Estudios sobre el Alcohol, el Alcoholismo y las otras Toxicomanías España Erdozain, Amaia M.; Callado, Luis F. Neurobiological alterations in alcohol addiction: a review Adicciones, vol. 26, núm. 4, octubre-diciembre, 2014, pp. 360-370 Sociedad Científica Española de Estudios sobre el Alcohol, el Alcoholismo y las otras Toxicomanías Palma de Mallorca, España Available in: http://www.redalyc.org/articulo.oa?id=289132934009 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative revisión adicciones vol. 26, nº 3 · 2014 Neurobiological alterations in alcohol addiction: a review Alteraciones neurobiológicas en el alcoholismo: revisión Amaia M. Erdozain*,*** and Luis F. Callado*,** *Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Bizkaia, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain. **Biocruces Health Research Institute, Bizkaia, Spain. ***Neuroscience Paris Seine, Université Pierre et Marie Curie, Paris, France Resumen Abstract Todavía se desconoce el mecanismo exacto mediante el cual el etanol The exact mechanism by which ethanol exerts its effects on the brain produce sus efectos en el cerebro. Sin embargo, hoy en día se sabe is still unknown. However, nowadays it is well known that ethanol que el etanol interactúa con proteínas específicas de la membrana interacts with specific neuronal membrane proteins involved in neuronal, implicadas en la transmisión de señales, produciendo así signal transmission, resulting in changes in neural activity. -
Cholesterol Modulates the Recruitment of Kv1.5 Channels from Rab11-Associated Recycling Endosome in Native Atrial Myocytes
Cholesterol modulates the recruitment of Kv1.5 channels from Rab11-associated recycling endosome in native atrial myocytes Elise Balsea,b, Saïd El-Haoua,b, Gilles Dillaniana,b, Aure´ lien Dauphinc, Jodene Eldstromd, David Fedidad, Alain Coulombea,b, and Ste´ phane N. Hatema,b,1 aInstitut National de la Sante´et de la Recherche Me´dicale, Unite´Mixte de Recherche Scientifique-956, 75013 Paris, France; bUniversite´Pierre et Marie Curie, Paris-6, Unite´Mixte de Recherche Scientifique-956, 75013 Paris, France; cPlate-forme imagerie cellulaire IFR14, 75013 Paris, France; and dDepartment of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada V6T 1Z3 Edited by Lily Y. Jan, University of California, San Francisco, CA, and approved June 19, 2009 (received for review March 17, 2009) Cholesterol is an important determinant of cardiac electrical proper- important role in the regulation of expression of KCNQ1/KCNE1, ties. However, underlying mechanisms are still poorly understood. pacemaker HCN channels and Kv1.5 channels. This process in- Here, we examine the hypothesis that cholesterol modulates the volves several Rab-GTPases (8–10). Rab-GTPases regulate the turnover of voltage-gated potassium channels based on previous trafficking of vesicles between plasma membrane and intracellular observations showing that depletion of membrane cholesterol in- compartments by regulating sorting, tethering and docking of creases the atrial repolarizing current IKur. Whole-cell currents and trafficking vesicles. Rab4, associated with the early endosome (EE), single-channel activity were recorded in rat adult atrial myocytes mediates the fast recycling process while Rab11, linked to the (AAM) or after transduction with hKv1.5-EGFP. -
Mechanism-Specific Assay Design Facilitates the Discovery of Nav1.7
Mechanism-specific assay design facilitates the PNAS PLUS discovery of Nav1.7-selective inhibitors Tania Chernov-Rogana, Tianbo Lia, Gang Lua, Henry Verschoofb, Kuldip Khakhb, Steven W. Jonesa, Maureen H. Beresinia, Chang Liua, Daniel F. Ortwinec, Steven J. McKerrallc, David H. Hackosd, Daniel Sutherlinc, Charles J. Cohenb, and Jun Chena,1 aDepartment of Biochemical and Cellular Pharmacology, Genentech Inc., San Francisco, CA 94080; bXenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada; cDepartment of Chemistry, Genentech Inc., San Francisco, CA 94080; and dDepartment of Neuroscience, Genentech Inc., San Francisco, CA 94080 Edited by Bruce P. Bean, Harvard Medical School, Boston, MA, and approved December 11, 2017 (received for review August 30, 2017) Many ion channels, including Nav1.7, Cav1.3, and Kv1.3, are linked therefore are nonselective (14). Recently, a group of arylsulfo- to human pathologies and are important therapeutic targets. To namides was identified as selective Nav1.7 inhibitors (15, 16). develop efficacious and safe drugs, subtype-selective modulation These compounds were discovered empirically, before our cur- is essential, but has been extremely difficult to achieve. We rent understanding that they bind to the voltage-sensing domain postulate that this challenge is caused by the poor assay design, 4 (VSD4) instead of the central cavity. However, PF-771, the and investigate the Nav1.7 membrane potential assay, one of the most advanced compound, was recently halted from clinical most extensively employed screening assays in modern drug development, raising concerns about this chemical class. discovery. The assay uses veratridine to activate channels, and To identify subtype-selective chemical scaffolds, large libraries compounds are identified based on the inhibition of veratridine- of compounds, sometimes exceeding millions of individual evoked activities. -
A Randomized, Double-Blind, Placebo Controlled, Cross-Over Trial of Quinidine in Genetic Epilepsy Due to KCNT1 Mutations
A trial of quinidine in genetic epilepsy A randomized, double-blind, placebo controlled, cross-over trial of quinidine in genetic epilepsy due to KCNT1 mutations Principal Investigator – Dr Saul Mullen Associate Investigators – Prof Ingrid Scheffer, Prof Samuel Berkovic, Dr Patrick Carney, Version 4 19th November, 2014 Page 1 of 14 Version 4, November 2014 A trial of quinidine in genetic epilepsy Introduction Epilepsy is defined by repeated, unprovoked seizures and is a major global health problem with a lifetime incidence of over 3% 1. Epilepsy is not, however, a uniform condition but rather a collection of syndromes with widely variable course, severity and underlying causes. Amongst these causes of epilepsy, inherited factors are prominent. The genetics of most inherited epilepsies is likely complex with multiple genes interacting with environmental factors to produce disease. An increasing number of monogenic epilepsies are however recognised. The majority of genes carrying epilepsy- causing mutations are neuronal ion channel subunits, thus leading to effects on either synaptic transmission or action potential firing. At present, the vast majority of epilepsy therapies take little account of the underlying causes. Anti- epileptic drugs are largely developed and tested in broad cohorts of epilepsy with mixed aetiologies. This has led to drugs each individually usable in most patients but with modest efficacy at best. Tailored drug therapies are starting to emerge for genetic epilepsies. For instance, in tuberous sclerosis complex, genetic abnormalities of the functional cascade associated with Mammalian Target of Rapamycin (mTOR) protein lead to the disease. Treatment with a specific inhibitor of this pathway, everolimus, leads to improved outcomes both in terms of seizures and secondary development of tumours 2.